Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning

L M Morsink; J van Doesum; G Choi; C L E Hazenberg; A Biswana; F Meppelink; L B Bungener; A J A Lambeck; G Huls

doi:10.1038/s41408-021-00605-1

Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning

Blood Cancer J. 2022 Jan 12;12(1):6. doi: 10.1038/s41408-021-00605-1.

Authors

L M Morsink^{1

2}, J van Doesum^{3

4}, G Choi^{3

4}, C L E Hazenberg^{3

4}, A Biswana^{3

4}, F Meppelink^{3

4}, L B Bungener^{4

5}, A J A Lambeck^{4

5}, G Huls^{3

4}

Affiliations

¹ Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. l.m.morsink@umcg.nl.
² University of Groningen, Groningen, the Netherlands. l.m.morsink@umcg.nl.
³ Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
⁴ University of Groningen, Groningen, the Netherlands.
⁵ Department of Laboratory Medicine, University Medical Center Groningen, Groningen, the Netherlands.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibody Formation
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / therapeutic use*
Cyclophosphamide / therapeutic use*
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunosuppressive Agents / therapeutic use*
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Retrospective Studies
Tacrolimus / therapeutic use
Transplantation Conditioning
Transplantation, Homologous
Young Adult

Substances

COVID-19 Vaccines
Immunosuppressive Agents
Cyclophosphamide
Tacrolimus